Transcript Jean-Marc_Jacque_Nanobio

Viruses and Nanobiology
Active compounds
• Antiviral Drugs
• siRNA
• miRNA
• DNA
Access to “viral sanctuaries”
(CNS, lymph nodes, tissue)
HIV
FIV
1.
2.
3.
4.
5.
6.
7.
Ability to efficiently access tissues
Ability to traverse the blood brain barrier
Solubility, Toxicity, Concentration
Rate of release
Protection of active compounds (siRNA, miRNA,
labile compounds)
Specific targeting of infected cells (particles
coating)
Combination of antivirals at lower doses reducing
therapy-related side-effects
Active compounds
Nanoparticles
Lymph nodes
Advantages of encapsulating active
compounds in nanoparticles
Brain
Lungs
HIV
FIV
Air borne and respiratory viruses
HIV
FIV
Viruses and Nanobiology
Experimental plan
Enhancing the efficiency
of antiviral drug delivery
Active compounds
Nanoparticles
Active compounds
•
Currently available
and potential new
Antiviral Drugs
•
siRNA
•
miRNA
•
DNA
•One of the central features of HIV infection is
that, in addition to targeting CD4 T-cells, the virus
has the ability to infect the long-lived cell subset
of the monocyte-macrophage lineage. While Tcells are quickly killed by the infection, this
cellular subset appears to be the main reservoir
for active virus replication even under highly
active antiretroviral therapies.
•Resident macrophages are found deep into
tissues where drug availability is reduced and
more importantly in the brain (microglia) where
drugs are excluded by the blood brain barrier
AIMS:
Periphery•Deliver active compounds
into difficult to access tissues
•Specifically target infected
cells
CNS•Ability and kinetics of “in
brain” delivery
•Efficiency of combination
therapies in the brain